The short version of analytical methods fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-03. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The Chinese Chemical Society (CCS; simplified Chinese: 中国化学会; traditional Chinese: 中國化學會) lays out a set of rules based on those given by the International Union of Pure and Applied Chemistry (IUPAC) for the purpose of systematic organic nomenclature in Chinese. The chemical names derived from these rules are meant to correspond with the English IUPAC name in a manner that is close to one-to-one, while being adapted to and taking advantage of the logographic nature of the Chinese written language. A standard set of characters invented during the 20th century, along with characters for the chemical elements and characters corresponding to standard chemical prefixes and suffixes, are used for this purpose.
=== Cancer === In normal cells, TGF-β, acting through its signaling pathway, stops the cell cycle at the G1 stage to stop proliferation, induce differentiation, or promote apoptosis. In many cancer cells, parts of the TGF-β signaling pathway are mutated, and TGF-β no longer controls the cell. These cancer cells proliferate. The surrounding stromal cells (fibroblasts) also proliferate. Both cells increase their production of TGF-β. This TGF-β acts on the surrounding stromal cells, immune cells, endothelial and smooth-muscle cells. It causes immunosuppression and angiogenesis, which makes the cancer more invasive. TGF-β also converts effector T-cells, which normally attack cancer with an inflammatory (immune) reaction, into regulatory (suppressor) T-cells, which turn off the inflammatory reaction. Normal tissue integrity is preserved by feedback interactions between different cell types that express adhesion molecules and secrete cytokines. Disruption of these feedback mechanisms in cancer damages a tissue. When TGF-β signaling fails to control NF-κB activity in cancer cells, this has at least two potential effects: first, it enables the malignant tumor to persist in the presence of activated immune cells, and second, the cancer cell outlasts immune cells because it survives in the presence of apoptotic, and anti-inflammatory mediators. Furthermore, forkhead box protein 3 (FOXP3) as a transcription factor is an essential molecular marker of regulatory T (Treg) cells.
Ninnu Kori (transl. Wanting you) is a 2017 Indian Telugu-language romantic comedy drama film directed by debutant Shiva Nirvana from a screenplay written by Kona Venkat. Produced by DVV Danayya under DVV Entertainments, the film stars Nani, Nivetha Thomas and Aadhi Pinisetty while Murali Sharma and Tanikella Bharani play supporting roles. Gopi Sunder composed the music. Prawin Pudi and Karthik Ghattamaneni are the editor and cinematographer of the film respectively. The plot revolves around Uma (Nani), Pallavi (Thomas), and Arun (Pinisetty). When Uma declines her proposal to elope, Pallavi marries Arun and emigrates to the US. Uma who still is in love with Pallavi also lands up in the US a year later in the hope of getting her back. The film was commercially successful, grossing over ₹52 crore at the box office. A Tamil-language remake titled Thalli Pogathey was released in 2021.
Sources: en.wikipedia.org
=== Antibody detection === A benefit of antibody detection (ELISA) is that protein identification on a microorganism becomes faster than a western blot. Antibody detection works by attaching an indicator to an antibody with a known specificity and observing whether the antibody attaches. ELISA can also indicate viral presence and is highly specific, having a detection specificity of 10−9-10−12 moles per litre detection. By knowing the epitope sequence of the antibody, ELISA can also be used for antigen detection in a sample.
Throughout the year 2000, ETA committed several attacks against leaders and elected officials of the "constitutionalist" parties that had opposed the "Lizarra Pact" and the PP and the PSOE decided to sign an Antiterrorist Pact, which neither the PNV nor EA joined. This pact, together with the legal encirclement of Batasuna, and the increasing police effectiveness weakened ETA to such an extent that the number of attacks was reduced. However, the confrontation between "nationalists" and "constitutionalists" did not diminish as was evidenced in the Basque elections of May 2001 in which the "nationalist front" triumphed, and the "peneuvist" Juan José Ibarretxe assumed the presidency of the Basque government. As a result of the relative failure of the "constitutionalist front" in the Basque elections of May 2001, the PP government proposed the outlawing of Herri Batasuna ─ at that time integrated in the Euskal Herritarrok coalition ─ for which it agreed with the PSOE and CiU a new Law of Political Parties. Thus, after the attack perpetrated by ETA in Santa Pola in August 2002 ─ which caused the death of two people and which Batasuna did not condemn ─ the process of outlawing began, which was accompanied by the "suspension" of Batasuna's activities by order of Judge Garzón, having found evidence of its connection with ETA. In early 2003, the Supreme Court declared Batasuna illegal as it was considered the "political arm" of ETA.
On the basis of the data available, the Panel concludes that a cause-and-effect relationship has been established between the consumption of beta-glucans and the "reduction of blood cholesterol concentrations." The following wording reflects the scientific evidence: "Regular consumption of beta-glucans contributes to maintenance of normal blood cholesterol concentrations." In order to bear the claim, foods should provide at least 3 g/d of beta-glucans from oats, oat bran, barley, barley bran, or mixtures of non-processed or minimally processed beta-glucans in one or more servings. The target population is adults with normal or mildly elevated blood cholesterol concentrations. In November 2011, the EU Commission published its decision in favour of oat beta-glucans with regard to Article 14 of the EC Regulation on the labelling of foodstuffs with nutrition and health claim statements permitting oat beta-glucan to be described as beneficial to health. Following the opinion of the Panel on Dietetic Products, Nutrition and Allergies (NDA) the EFSA and the Regulation (EU) no. 1160/2011 of the Commission, foodstuffs through which 3 g/day of oat beta-glucan are consumed (1 g of oat beta-glucan per portion) are allowed to display the following health claim: "Oat beta-glucan reduces the cholesterol level in the blood.
Sources: en.wikipedia.org
A memorial collection of scientific papers contributed by former pupils and colleagues of Robertson, edited by Sir Charles James Martin and Hedley R. Marston, was published in January 1932 as a special issue of The Australian Journal of Experimental Biology and Medical Science. A memorial window, commissioned by his wife — designed and produced by Edith Lungley, a member of the British Society of Master Glass Painters — was presented to the University of Adelaide, and was unveiled in the Mitchell Building at a ceremony on 18 March 1932 by Sir George Murray, the university's Chancellor. The Medical Sciences Club of South Australia sponsored the annual Brailsford Robertson Memorial Lecture in Robertson's memory. Notable lecturers have been: Sir Howard Florey (1944), Edward Slater (1957)[9], Frank G. Young (1960)[10], Derek Denny-Brown (1964)[11], M.F.A. Woodruff (1965)[12], Stephen Boyden (1968)[13], Geoffrey Burnstock (1971), Frank Macfarlane Burnet (1976)[14], and John B. West (1978). In 2001, the Brailsford Robertson Award was jointly created by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and the University of Adelaide specifically to encourage collaborative research in areas of health identified as strategic priorities by the CSIRO Food and Nutritional Sciences division and the University of Adelaide. In 2001, the former CSIRO Division of Animal Nutrition Building on the University of Adelaide's campus was re-named the Brailsford Robertson Building.
=== tim-tin === Tim-AK Timecelles timefurone (INN) timegadine (INN) timelotem (INN) Timentin timepidium bromide (INN) timiperone (INN) timirdine (INN) timobesone (INN) timofibrate (INN) Timolide timolol (INN) timonacic (INN) timoprazole (INN) Timoptic tinabinol (INN) Tinactin Antifungal Tinaderm Tinamed tinazoline (INN) TinBen Tindal Tindamax Ting tinidazole (INN) tinisulpride (INN) tinofedrine (INN) tinoridine (INN) Tinver tinzaparin sodium (INN)
Cipepofol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known as ciprofol or by its developmental code name HSK3486, sold under the brand name Cypsedo, is a general anesthetic related to propofol which is used for anesthesia and sedation. The drug is used by intravenous infusion. A short-acting and highly selective GABAA positive allosteric modulator, ciprofol is 4 to 6 times more potent than other phenol derivatives such as propofol or fospropofol. In May 2026, cipepofol was approved for medical use in the United States. Manufactured by Haisco Pharmaceutical Group, ciprofol underwent phase I and II trials in Australia and China.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.